EU/3/18/1997

About

On 21 March 2018, orphan designation (EU/3/18/1997) was granted by the European Commission to QRC Consultants Ltd, United Kingdom, for miransertib for the treatment of Proteus syndrome.

Key facts

Active substance
Miransertib
Disease / condition
Treatment of Proteus syndrome
Date of decision
21/03/2018
Outcome
Positive
Orphan decision number
EU/3/18/1997

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

QRC Consultants Ltd
Silvaco Technology Centre
Compass Point
St Ives
Cambridgeshire PE27 5JL
United Kingdom
Tel. +44 (0)1480 309 349
E-mail: enquiries@qrcc.co.uk

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating